Carlson Capital Management Has Cut Its Procter & Gamble Co (PG) Stake; 4 Analysts Bullish Progenics Pharmaceuticals, Inc. (PGNX)

June 19, 2017 - By Adrian Erickson

Carlson Capital Management decreased Procter & Gamble Co (PG) stake by 39.73% reported in 2016Q4 SEC filing. Carlson Capital Management sold 4,277 shares as Procter & Gamble Co (PG)’s stock declined 5.32%. The Carlson Capital Management holds 6,487 shares with $545,000 value, down from 10,764 last quarter. Procter & Gamble Co now has $230.03 billion valuation. The stock increased 0.31% or $0.28 during the last trading session, reaching $89.66. About 39 shares traded. Procter & Gamble Co (NYSE:PG) has risen 7.54% since June 19, 2016 and is uptrending. It has underperformed by 9.16% the S&P500.

Among 4 analysts covering Progenics Pharm (NASDAQ:PGNX), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Progenics Pharm had 6 analyst reports since August 6, 2015 according to SRatingsIntel. The company was downgraded on Friday, August 7 by Zacks. The stock of Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) earned “Buy” rating by Needham on Friday, August 7. The firm earned “Strong Buy” rating on Monday, February 6 by Needham. As per Friday, October 23, the company rating was upgraded by Jefferies. On Thursday, October 27 the stock rating was initiated by Aegis Capital with “Buy”. The stock of Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) earned “Buy” rating by Brean Capital on Thursday, August 6. See Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) latest ratings:

06/02/2017 Broker: Needham Old Rating: Buy New Rating: Strong Buy Old Target: $11 New Target: $14 Upgrade

Investors sentiment increased to 1.22 in Q4 2016. Its up 0.05, from 1.17 in 2016Q3. It increased, as 12 investors sold Progenics Pharmaceuticals, Inc. shares while 38 reduced holdings. 31 funds opened positions while 30 raised stakes. 59.59 million shares or 0.65% more from 59.20 million shares in 2016Q3 were reported. Prelude Management Limited holds 0.01% or 5,100 shares in its portfolio. Globeflex Capital Limited Partnership has invested 0.34% of its portfolio in Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX). Millennium Mgmt Lc has 334,670 shares for 0.01% of their portfolio. Bnp Paribas Arbitrage holds 1,101 shares. Great West Life Assurance Commerce Can owns 12,200 shares. Rice Hall James Associates Ltd Liability stated it has 0.48% in Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX). Panagora Asset Management Inc has 0% invested in Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) for 3,581 shares. 14,718 were reported by Duncker Streett And. Susquehanna Intl Gru Ltd Liability Partnership, Pennsylvania-based fund reported 197,616 shares. Eagle Asset stated it has 2.67M shares or 0.15% of all its holdings. 22,600 were accumulated by Price T Rowe Assocs Inc Md. Oxford Asset Management invested in 275,415 shares. Blackrock Advsr Lc invested in 0% or 54,522 shares. Moreover, Sg Americas Limited Com has 0% invested in Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) for 26,951 shares. Morgan Stanley holds 0% of its portfolio in Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) for 376,886 shares.

The stock decreased 0.89% or $0.06 on June 16, reaching $6.69. About shares traded. Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) has risen 48.41% since June 19, 2016 and is uptrending. It has outperformed by 31.71% the S&P500.

Since February 7, 2017, it had 0 insider buys, and 2 selling transactions for $9.23 million activity. Broadfin Healthcare Master Fund Ltd sold 351,300 shares worth $3.41 million.

Progenics Pharmaceuticals, Inc. is engaged in developing medicines and other products for targeting and treating cancer. The company has market cap of $465.63 million. The Company’s pipeline includes therapeutic agents designed to target cancer ; prostate specific membrane antigen (PSMA)-targeted imaging agents for prostate cancer (1404 and PyL), and imaging analysis tools. It has a 64.59 P/E ratio. It also includes commercial product, RELISTOR (methylnaltrexone bromide) for opioid-induced constipation.

Since February 2, 2017, it had 0 insider purchases, and 19 sales for $24.25 million activity. $88,011 worth of stock was sold by TASTAD CAROLYN M on Wednesday, February 15. Louvet Patrice sold $4.26M worth of Procter & Gamble Co (NYSE:PG) on Tuesday, May 23. Skoufalos Ioannis had sold 3,879 shares worth $334,265 on Monday, May 22. 2,915 shares were sold by FergusonMchugh MaryLynn, worth $265,847. Bishop Steven D also sold $233,011 worth of Procter & Gamble Co (NYSE:PG) on Monday, May 1. Fish Kathleen B had sold 743 shares worth $67,758. 5,000 shares were sold by Posada Juan Fernando, worth $440,000.

Analysts await Procter & Gamble Co (NYSE:PG) to report earnings on August, 1. They expect $0.79 EPS, 0.00% or $0.00 from last year’s $0.79 per share. PG’s profit will be $2.03 billion for 28.37 P/E if the $0.79 EPS becomes a reality. After $0.96 actual EPS reported by Procter & Gamble Co for the previous quarter, Wall Street now forecasts -17.71% negative EPS growth.

Among 22 analysts covering Proctor & Gamble (NYSE:PG), 10 have Buy rating, 1 Sell and 11 Hold. Therefore 45% are positive. Proctor & Gamble had 48 analyst reports since August 4, 2015 according to SRatingsIntel. On Tuesday, September 1 the stock rating was initiated by Morgan Stanley with “Equal Weight”. The company was upgraded on Wednesday, January 27 by Goldman Sachs. The stock has “Sector Perform” rating by RBC Capital Markets on Tuesday, October 27. The stock of Procter & Gamble Co (NYSE:PG) earned “Neutral” rating by Sterne Agee CRT on Tuesday, July 21. Suntrust Robinson upgraded the stock to “Buy” rating in Tuesday, September 8 report. Citigroup initiated the shares of PG in report on Tuesday, November 17 with “Neutral” rating. The firm has “Hold” rating given on Wednesday, December 21 by Stifel Nicolaus. The firm has “Buy” rating given on Tuesday, August 25 by Vetr. The stock of Procter & Gamble Co (NYSE:PG) earned “Market Perform” rating by Wells Fargo on Tuesday, November 15. On Monday, October 26 the stock rating was maintained by UBS with “Neutral”.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: